Page 85 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

PET/CT interobserver agreement in DLBCL
P*
P*
Table 1. Interobserver agreement on dichotomized DS, by baseline modality.
0.605 0.486 0.332 or PET/CT (n=343) 18 94.5 (91.7-97.4) 73.9 (62.0-85.9) 91.0 (87.8-94.1) Baseline F-FDG PET 17.3 96.3 (89.5-97.9) 82.9 (59.2-90.8) 93.9 (89.0-98.7) Baseline CT only (n=114) 18.0 EoT- PET/CT 0.947 95.0 (92.6-97.3) 0.347 76.3 (66.3-86.2) 0.799 91.7 (89.0-94.3) (n=457 ) Total 17.5 †Prevalence of positive scans was calculated as sum of number of scans in which both reviewers scored positively and half of scans with discrepancies divided by total number 18 or PET/CT (n=357) 92.0 (88.6-95.4) 75.7 (66.2-85.2) 88.0 (84.4-91.5) Baseline F-FDG PET 24.8 92.0 (85.8-98.3) 65.0 (41.6-88.4) 87.0 (80.2-93.8) Baseline CT only (n=108) 18.5 *P-values of χ2 test refer to comparison of baseline CT vs. baseline PET or PET/CT. 92.0 (89.1-95.0)
73.7 (65.0-82.5)
87.7 (84.7-90.8)
I- PET/CT
Data are percentages, with 95%CIs in parentheses. Total
(n=465)
23.3
DS 1-3= negative; DS 4-5= positive. Positivity†
Percentage OA
Percentage PA
Percentage NA
of scans.
Agreement
83
4